Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma Dietrich J; Wang D; Batchelor TTExpert Opin Investig Drugs 2009[Oct]; 18 (10): 1549-57BACKGROUND: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas. OBJECTIVE: This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase. METHODS: We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas. RESULTS/CONCLUSION: Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.|Angiogenesis Inhibitors/adverse effects/*pharmacology/therapeutic use[MESH]|Animals[MESH]|Antineoplastic Agents/adverse effects/pharmacology/therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Drug Evaluation, Preclinical[MESH]|Glioblastoma/blood supply/*drug therapy[MESH]|Humans[MESH]|Quinazolines/adverse effects/*pharmacology/therapeutic use[MESH]|Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors[MESH] |
